Graig Suvannavejh
Stock Analyst at Mizuho
(3.52)
# 901
Out of 4,981 analysts
160
Total ratings
50.41%
Success rate
4.76%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Graig Suvannavejh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IDYA IDEAYA Biosciences | Maintains: Outperform | $43 → $44 | $24.63 | +78.64% | 2 | Sep 12, 2025 | |
| BTAI BioXcel Therapeutics | Maintains: Neutral | $2 → $4 | $3.11 | +28.62% | 9 | Sep 12, 2025 | |
| KALA KALA BIO | Initiates: Outperform | $30 | $18.62 | +61.12% | 1 | Sep 8, 2025 | |
| INSM Insmed | Maintains: Outperform | $130 → $165 | $145.93 | +13.07% | 11 | Aug 13, 2025 | |
| ALEC Alector | Upgrades: Outperform | $2.5 → $3.5 | $2.75 | +27.27% | 5 | Jul 28, 2025 | |
| NMRA Neumora Therapeutics | Maintains: Outperform | $4 → $5 | $1.62 | +208.64% | 2 | Jul 16, 2025 | |
| ADVM Adverum Biotechnologies | Maintains: Outperform | $16 → $12 | $3.02 | +297.35% | 5 | Jun 26, 2025 | |
| ADAP Adaptimmune Therapeutics | Downgrades: Neutral | $1.5 → $0.5 | $0.06 | +792.86% | 3 | Jun 26, 2025 | |
| IMRX Immuneering | Maintains: Outperform | $8 → $10 | $8.49 | +17.79% | 2 | Jun 18, 2025 | |
| CRVS Corvus Pharmaceuticals | Maintains: Outperform | $12 → $11 | $5.83 | +88.68% | 3 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $26 | $13.35 | +94.76% | 5 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $44 → $48 | $32.39 | +48.19% | 18 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $20 | $24.85 | -19.52% | 7 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $8 | $11.65 | -31.33% | 7 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $33 | $35.69 | -7.54% | 8 | Apr 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $212 → $216 | $118.42 | +82.40% | 21 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7 → $7.6 | $1.38 | +450.72% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $9.50 | +678.95% | 1 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $5 → $0.5 | $0.36 | +38.89% | 3 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $44 → $49 | $76.90 | -36.28% | 6 | Jul 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $16 | $5.82 | +174.91% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $10 | $7.23 | +38.41% | 5 | Nov 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $1 | $6.17 | -83.79% | 5 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $35 | $96.22 | -63.63% | 5 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $8 | $9.25 | -13.51% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $71 → $57 | $51.13 | +11.48% | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $5 | $32.16 | -84.45% | 4 | Apr 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $8.92 | +281.17% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $6.09 | +359.77% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $31 | $14.24 | +117.70% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $19 | $1.74 | +991.95% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $4.75 | $2.00 | +137.50% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $36 | $17.29 | +108.21% | 2 | Nov 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $32.05 | - | 1 | Oct 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $37 | $1.13 | +3,174.34% | 1 | Oct 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $128 | $126.16 | +1.46% | 1 | Sep 14, 2020 |
IDEAYA Biosciences
Sep 12, 2025
Maintains: Outperform
Price Target: $43 → $44
Current: $24.63
Upside: +78.64%
BioXcel Therapeutics
Sep 12, 2025
Maintains: Neutral
Price Target: $2 → $4
Current: $3.11
Upside: +28.62%
KALA BIO
Sep 8, 2025
Initiates: Outperform
Price Target: $30
Current: $18.62
Upside: +61.12%
Insmed
Aug 13, 2025
Maintains: Outperform
Price Target: $130 → $165
Current: $145.93
Upside: +13.07%
Alector
Jul 28, 2025
Upgrades: Outperform
Price Target: $2.5 → $3.5
Current: $2.75
Upside: +27.27%
Neumora Therapeutics
Jul 16, 2025
Maintains: Outperform
Price Target: $4 → $5
Current: $1.62
Upside: +208.64%
Adverum Biotechnologies
Jun 26, 2025
Maintains: Outperform
Price Target: $16 → $12
Current: $3.02
Upside: +297.35%
Adaptimmune Therapeutics
Jun 26, 2025
Downgrades: Neutral
Price Target: $1.5 → $0.5
Current: $0.06
Upside: +792.86%
Immuneering
Jun 18, 2025
Maintains: Outperform
Price Target: $8 → $10
Current: $8.49
Upside: +17.79%
Corvus Pharmaceuticals
May 20, 2025
Maintains: Outperform
Price Target: $12 → $11
Current: $5.83
Upside: +88.68%
May 16, 2025
Maintains: Outperform
Price Target: $30 → $26
Current: $13.35
Upside: +94.76%
May 15, 2025
Maintains: Outperform
Price Target: $44 → $48
Current: $32.39
Upside: +48.19%
May 14, 2025
Maintains: Neutral
Price Target: $30 → $20
Current: $24.85
Upside: -19.52%
May 14, 2025
Maintains: Outperform
Price Target: $7 → $8
Current: $11.65
Upside: -31.33%
Apr 7, 2025
Maintains: Neutral
Price Target: $38 → $33
Current: $35.69
Upside: -7.54%
Mar 27, 2025
Maintains: Outperform
Price Target: $212 → $216
Current: $118.42
Upside: +82.40%
Nov 18, 2024
Upgrades: Buy
Price Target: $7 → $7.6
Current: $1.38
Upside: +450.72%
Sep 20, 2024
Reiterates: Outperform
Price Target: $74
Current: $9.50
Upside: +678.95%
Sep 19, 2024
Downgrades: Neutral
Price Target: $5 → $0.5
Current: $0.36
Upside: +38.89%
Jul 22, 2024
Maintains: Neutral
Price Target: $44 → $49
Current: $76.90
Upside: -36.28%
May 16, 2024
Maintains: Buy
Price Target: $14 → $16
Current: $5.82
Upside: +174.91%
Nov 27, 2023
Maintains: Buy
Price Target: $17 → $10
Current: $7.23
Upside: +38.41%
Jun 5, 2023
Downgrades: Neutral
Price Target: $17 → $1
Current: $6.17
Upside: -83.79%
Nov 10, 2022
Maintains: Buy
Price Target: $31 → $35
Current: $96.22
Upside: -63.63%
Nov 10, 2022
Maintains: Neutral
Price Target: $9 → $8
Current: $9.25
Upside: -13.51%
May 24, 2022
Maintains: Buy
Price Target: $71 → $57
Current: $51.13
Upside: +11.48%
Apr 19, 2022
Maintains: Sell
Price Target: $8 → $5
Current: $32.16
Upside: -84.45%
Jun 1, 2021
Initiates: Buy
Price Target: $34
Current: $8.92
Upside: +281.17%
Apr 20, 2021
Initiates: Neutral
Price Target: $28
Current: $6.09
Upside: +359.77%
Apr 19, 2021
Initiates: Neutral
Price Target: $31
Current: $14.24
Upside: +117.70%
Mar 2, 2021
Initiates: Sell
Price Target: $19
Current: $1.74
Upside: +991.95%
Nov 24, 2020
Initiates: Neutral
Price Target: $4.75
Current: $2.00
Upside: +137.50%
Nov 9, 2020
Upgrades: Buy
Price Target: $36
Current: $17.29
Upside: +108.21%
Oct 21, 2020
Downgrades: Sell
Price Target: n/a
Current: $32.05
Upside: -
Oct 20, 2020
Initiates: Neutral
Price Target: $37
Current: $1.13
Upside: +3,174.34%
Sep 14, 2020
Downgrades: Sell
Price Target: $128
Current: $126.16
Upside: +1.46%